title: High-dose cisplatin with dipyridamole in advanced non-small cell lung cancer. A Grupo Oncológico Cooperativo del Sur study.
abstract: From March 1991 to October 1992, 41 patients with advanced non-small cell lung cancer (NSCLC) (20 stage IIIB and 21 stage IV) received a regimen consisting of cisplatin (CP) 100 mg/m2 i.v. days 1 and 8, and dipyridamole (DPD) 100 mg p.o. 75 minutes before CP, and then at hours 6, 12, and 18 as first-line chemotherapy. Cycles were repeated every 28 days for a total of 3. Median age was 56 years (range: 40-70). All patients had a performance status 0 to 1 and a weight loss < or = 10%. Squamous-cell carcinoma was diagnosed in 19 patients; adenocarcinoma in 16, and large-cell carcinoma in 6. A total of 37 patients were fully evaluable for response, whereas 39 were assessable for toxicity. No complete responses were observed: 5 patients (14%) achieved partial response; 23 patients (62%) showed no change, and progressive disease was observed in 9 (24%). The median time to treatment failure was 4 months, whereas median survival was 8 months. The average dose intensity received at the end of the third course of therapy was 46 mg/m2/week. There were no drug-related deaths. Toxicity was mild to moderate, with a high incidence of ototoxicity (54%) and emesis (67%). In conclusion, these results failed to demonstrate any significant advantage from a high-dose CP regimen modulated by DPD in patients with advanced NSCLC.
authors.affiliation: Grupo Oncológico Cooperativo del Sur (GOCS), Neuqeén, Argentina.
authors.forename: C T
authors.initials: CT
authors.lastname: Vallejo
authors.forename: M G
authors.initials: MG
authors.lastname: Rabinovich
authors.forename: J E
authors.initials: JE
authors.lastname: Perez
authors.forename: R
authors.initials: R
authors.lastname: Rodriguez
authors.forename: M R
authors.initials: MR
authors.lastname: Machiavelli
authors.forename: B A
authors.initials: BA
authors.lastname: Leone
authors.forename: A D
authors.initials: AD
authors.lastname: Romero
authors.forename: J A
authors.initials: JA
authors.lastname: Lacava
authors.forename: M A
authors.initials: MA
authors.lastname: Cuevas
authors.forename: M J
authors.initials: MJ
authors.lastname: Langhi
mesh_terms: D000328:Adult; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004176:Dipyridamole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D004176:Dipyridamole; D002945:Cisplatin